1. BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3‐YEAR FOLLOW‐UP FROM THE RIALTO TRIAL. (12th June 2019) Authors: Pettitt, A.; Kalakonda, N.; Cicconi, S.; Murphy, C.; Menon, G.; Coupland, S.E.; Oates, M.; Lin, K.; Pocock, C.; Jenkins, S.; Schuh, A.; Wandroo, F.; Rassam, S.; Duncombe, A.S.; Cervi, P.; Paneesha, S.; Aldouri, M.; Fox, C.; Knechtli, C.; Hamblin, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 217 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL. (June 2017) Authors: Pettitt, A.R.; Kalakonda, N.; Polydoros, F.; Bickerstaff, M.; Menon, G.; Coupland, S.E.; Oates, M.; Lin, K.; Pocock, C.; Jenkins, S.; Schuh, A.; Wandroo, F.; Rassam, S.; Duncombe, A.S.; Jenner, M.; Cervi, P.; Paneesha, S.; Aldouri, M.; Fox, C.P.; Knechtli, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMA. (12th June 2019) Authors: Pettitt, A.R.; Barrington, S.; Kalakonda, N.; Khan, U.T.; Jackson, R.; Carruthers, S.; Oates, M.; Lin, K.; Ardeshna, K.; Eyre, T.; Fox, C.P.; Kennedy, B.; Linton, K.; Malladi, R.; Menne, T.; Okosun, J.; Paneesha, S.; Rule, S.; Johnston, A.; Trotman, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP0297 EFFICACY AND SAFETY OF ROMOSOZUMAB AMONG POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND MILD-TO-MODERATE CHRONIC KIDNEY DISEASE. (2nd June 2020) Authors: Miller, P.; Adachi, J.; Albergaria, B. H.; Cheung, A. M.; Chines, A.; Gielen, E.; Langdahl, B.; Miyauchi, A.; Oates, M.; Reid, I.; Ruiz Santiago, N.; Vanderkelen, M.; Yang, W.; Yu, Z. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗